ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
www.immupharma.co.uk
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of biotechnology, companies often face unique challenges, particularly when it comes to navigating public markets and
ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.